Clinical trial · Observational
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
NCT05907447CI-TRIAL-00067294unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to retrospectively collect clinical information on patients with extranodal or rare lymphomas, and to explore the best treatment strategy for these lymphomas in the real-world population.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anaplastic Large Cell Lymphoma | Anaplastic Large Cell Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Angioimmunoblastic T-cell Lymphoma | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | ALIAS | 0.90 |
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Extranodal Lymphoma | Extranodal Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Intravascular Large B-Cell Lymphoma | Intravascular Large B-Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Marginal Zone Lymphoma | Marginal Zone Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Mucosa-Associated Lymphoid Tissue Lymphoma | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | ALIAS | 0.90 |
| NK/T-Cell Lymphoma, Nasal and Nasal-Type | Nasal Type Extranodal NK/T-Cell Lymphoma |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No interventions need to be specified for this study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall Survival (OS)
- timeFrame
- Baseline up to data cut-off (up to approximately 1 year)
- description
- Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause.
- measure
- Progression Free Survival (PFS)
- timeFrame
- Baseline up to data cut-off (up to approximately 1 year)
- description
- Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.
Secondary outcomes (2)
- measure
- Clinical characteristics form
- timeFrame
- Baseline up to data cut-off (up to approximately 1 year)
- description
- Clinical characteristics from data filled into registry forms by physicians and data managers, including but not limited to values of lactate dehydrogenase, clinical stage, performance status, age ≥ 60 years and number and location of extranodal localizations.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years (including 18 years old). 2. Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined; Or patients newly diagnosed with non-Hodgkin lymphoma of rare pathological types, including IVLBCL, SMZL, ALCL, AITL, MALTL. 3. Patients who have received systematic clinical treatment. 4. Patients with measurable lesions, at least containing one effective evaluation of efficacy. Exclusion Criteria: 1. Patients who only receive supportive treatment. 2. Patients who cannot obtain effective evaluation data of efficacy.
References
Publications (0)
Data not yet available
No reference posted for this study.